ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 230 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,374 | -21.6% | 8,142 | -3.4% | 0.00% | – |
Q2 2023 | $56,579 | -6.4% | 8,432 | +23.2% | 0.00% | – |
Q1 2023 | $60,442 | +14.9% | 6,845 | -0.6% | 0.00% | – |
Q4 2022 | $52,609 | -17.8% | 6,886 | -22.4% | 0.00% | – |
Q3 2022 | $64,000 | +100.0% | 8,876 | +127.6% | 0.00% | – |
Q2 2022 | $32,000 | -56.2% | 3,899 | -26.3% | 0.00% | – |
Q1 2022 | $73,000 | +37.7% | 5,293 | +176.7% | 0.00% | – |
Q4 2021 | $53,000 | -70.4% | 1,913 | -63.5% | 0.00% | – |
Q3 2021 | $179,000 | -43.2% | 5,246 | -32.0% | 0.00% | – |
Q2 2021 | $315,000 | -19.8% | 7,718 | -20.9% | 0.00% | – |
Q1 2021 | $393,000 | -33.2% | 9,760 | -1.7% | 0.00% | -100.0% |
Q4 2020 | $588,000 | +90.3% | 9,924 | +56.0% | 0.00% | – |
Q3 2020 | $309,000 | -4.0% | 6,362 | -4.1% | 0.00% | – |
Q2 2020 | $322,000 | +1688.9% | 6,635 | +922.3% | 0.00% | – |
Q1 2020 | $18,000 | -5.3% | 649 | +1.7% | 0.00% | – |
Q4 2019 | $19,000 | -5.0% | 638 | -0.5% | 0.00% | – |
Q3 2019 | $20,000 | – | 641 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
Triatomic Management LP | 102,889 | $560,745 | 0.39% |